87 related articles for article (PubMed ID: 28640134)
1. Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients.
Yang-Chun F; Zhen-Zhen C; Yan-Chun H; Xiu-Min M
Medicine (Baltimore); 2017 Jun; 96(25):e7270. PubMed ID: 28640134
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus type 16 L1/L2 DNA methylation shows weak association with cervical disease grade in young women.
Bryant D; Hibbitts S; Almonte M; Tristram A; Fiander A; Powell N
J Clin Virol; 2015 May; 66():66-71. PubMed ID: 25866341
[TBL] [Abstract][Full Text] [Related]
3. Human Papillomavirus 16 DNA Methylation Patterns and Investigation of Integration Status in Head and Neck Cancer Cases.
Zygouras I; Leventakou D; Pouliakis A; Panagiotou S; Tsakogiannis D; Konstantopoulos G; Logotheti E; Samaras M; Kyriakopoulou Z; Beloukas A; Pateras IS; Delides A; Psyrri A; Panayiotides IG; Yiangou M; Kottaridi C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834041
[TBL] [Abstract][Full Text] [Related]
4. Human Papillomavirus Type 16 L2 DNA Methylation in Exfoliated Cervical Cells From College-Age Women.
Anderson EL; Banister CE; Kassler S; Messersmith A; Pirisi L; Creek KE; Wyatt MD
J Low Genit Tract Dis; 2016 Oct; 20(4):332-7. PubMed ID: 27518844
[TBL] [Abstract][Full Text] [Related]
5. [Predictive markers of immunotherapy in cervical cancer].
Oliushina EM; Zavalishina LE; Andreeva YY; Kuznetsova OA; Moskvina LV; Frank GA
Arkh Patol; 2023; 85(5):5-12. PubMed ID: 37814844
[TBL] [Abstract][Full Text] [Related]
6. Combined HPV 16 E2 and L1 methylation predict response to treatment with cidofovir and imiquimod in patients with vulval intraepithelial neoplasia.
Hurt CN; Nedjai B; Alvarez-Mendoza C; Powell N; Tristram A; Jones S
Cancer Biomark; 2022; 35(2):143-153. PubMed ID: 35912731
[TBL] [Abstract][Full Text] [Related]
7. Naturally developed HPV16 antibodies and risk of newly detected cervical HPV infection outcomes.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H
J Med Virol; 2024 Apr; 96(4):e29608. PubMed ID: 38623750
[TBL] [Abstract][Full Text] [Related]
8. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.
Shi YY; Dong DR; Fan G; Dai MY; Liu M
Front Immunol; 2023; 14():1237964. PubMed ID: 37849747
[TBL] [Abstract][Full Text] [Related]
9. The Prevalence of Epstein - Barr Virus in Normal, Premalignant, and Malignant Uterine Cervical Samples in Iran.
Chavoshpour-Mamaghani S; Shoja Z; Jalilvand S
Intervirology; 2024 Apr; ():. PubMed ID: 38621370
[TBL] [Abstract][Full Text] [Related]
10. COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study.
Saldivar JS; Lopez D; Feldman RA; Tharappel-Jacob R; de la Rosa A; Terreros D; Baldwin WS
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S155-62. PubMed ID: 17826825
[TBL] [Abstract][Full Text] [Related]
11. Modulation of sHLA-G, PD-1, and PD-L1 Expression in Cervical Lesions Following Imiquimod Treatment and Its Association with Treatment Success.
Cokan A; da Silva NCH; Kavalar R; But I; Pakiž M; Andrade de Oliveira S; Dos Santos Gomes FO; da Silva RS; Peixoto CA; Lucena-Silva N
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610950
[TBL] [Abstract][Full Text] [Related]
12. The Micro-Immunotherapy Medicine 2LPAPI
Jacques C; Marchand F; Chatelais M; Albinet V; Coustal C; Floris I
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611099
[TBL] [Abstract][Full Text] [Related]
13. Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer.
Sivars L; Jylhä C; Crona Guterstam Y; Zupancic M; Lindqvist B; Nordenskjöld M; Tham E; Hellman K
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38669077
[TBL] [Abstract][Full Text] [Related]
14. Targeting cervical cancer with anti-PD-1 antibodies: what is new?
Greenman M; McNamara B; Mutlu L; Santin AD
Expert Opin Biol Ther; 2024 Mar; 24(3):111-114. PubMed ID: 38391293
[No Abstract] [Full Text] [Related]
15. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.
Läubli H; Hench J; Stanczak M; Heijnen I; Papachristofilou A; Frank S; Zippelius A; Stenner-Liewen F
J Immunother Cancer; 2017; 5():46. PubMed ID: 28642817
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer.
Meng Y; Liang H; Hu J; Liu S; Hao X; Wong MSK; Li X; Hu L
J Cancer; 2018; 9(16):2938-2945. PubMed ID: 30123362
[TBL] [Abstract][Full Text] [Related]
17. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions.
Allouch S; Malki A; Allouch A; Gupta I; Vranic S; Al Moustafa AE
Front Oncol; 2020; 10():914. PubMed ID: 32695664
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.
Cohen AC; Roane BM; Leath CA
Drugs; 2020 Feb; 80(3):217-227. PubMed ID: 31939072
[TBL] [Abstract][Full Text] [Related]
19. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.
Cai H; Yan L; Liu N; Xu M; Cai H
Biomed Pharmacother; 2020 Mar; 123():109790. PubMed ID: 31896065
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of cervical cancer.
Marret G; Borcoman E; Le Tourneau C
Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
[No Abstract] [Full Text] [Related]
[Next] [New Search]
